Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells

• Published in: Journal of Veterinary Medical Science Vol. 83; no. 10; pp. 1495 - 1499
• Main Authors: SAKAI, Osamu, OGINO, Shoji, TSUKUI, Toshihiro, IGASE, Masaya, MIZUNO, Takuya
• Format: Journal Article
• Language: English
• Published: Tokyo JAPANESE SOCIETY OF VETERINARY SCIENCE 2021; Japan Science and Technology Agency; The Japanese Society of Veterinary Science
• Subjects: adoptive immunotherapy; Antigens; canine; CD20; CD20 antigen; Cell therapy; chimeric antigen receptor T cell; Chimeric antigen receptors; Clinical Pathology; Lymphocytes; Lymphocytes B; Lymphocytes T; Lymphoma; Malignancy; Monoclonal antibodies; monoclonal antibody
• ISSN: 0916-7250; 1347-7439
• DOI: 10.1292/jvms.21-0326

Chimeric antigen receptor (CAR) CAR-T cell therapy targeting CD20 can be a novel adoptive cell therapy for canine patients with B-cell malignancy. After injection of the CAR-T cells in vivo, monitoring circulating CAR-T cells is essential to prove in vivo persistence of CAR-T cells. In this study, we developed a novel monoclonal antibody against canine CD20 CAR, whose single-chain variable fragment was derived from the our previously reported anti-canine CD20 therapeutic antibody. Furthermore, we proved that this monoclonal antibody can detect therapeutic anti-canine CD20 chimeric antibody in the serum from healthy beagle dogs injected with the therapeutic antibody for safety study. This monoclonal antibody is a useful tool for monitoring both canine CD20-CAR-T cells and anti-canine CD20 therapeutic antibody for canine lymphoma.